Low-dose diethylstilbestrol for the treatment of advanced prostate cancer
Autor: | L. Michael Glode, Julia Clemons, Dexiang Gao, Thomas W. Flaig |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2011 |
Předmět: |
Oncology
Male medicine.medical_specialty Urology Diethylstilbestrol Antineoplastic Agents Drug resistance Kaplan-Meier Estimate urologic and male genital diseases Article Prostate cancer Internal medicine medicine Humans Aged Retrospective Studies Aged 80 and over business.industry Low dose Prostatic Neoplasms Retrospective cohort study Middle Aged Prostate-Specific Antigen medicine.disease Prostate-specific antigen Drug Resistance Neoplasm Cohort Population study business medicine.drug |
Popis: | The purpose of this study was to assess the efficacy and safety of low-dose (1 mg) daily diethylstilbestrol (DES) for the treatment of castrate-resistant prostate cancer (CRPC).A retrospective chart review was performed on patients treated with low-dose DES who had CRPC despite anti-androgen withdrawal. The study population consists of 63 patients treated in the pre- and post-chemotherapy settings based on a database review; 58 had sufficient data for efficacy, all were analyzed for safety.A PSA decrease of ≥50% was observed in 19 of 49 pre-chemotherapy patients (39%) with a median time to progression (TTP) of 30 weeks (95% CI, 21.9, 68.7). A PSA decrease of50% was seen in another 16 patients (33%) with a median TTP of 16.4 weeks (95% CI, 13.0, 37.6). Fourteen patients (29%) had progressive disease by PSA testing; their median TTP was 6.9 weeks (95% CI, 5.6, 12.9). Thromboembolic events included 2 patients with DVTs and 1 patient who developed primary fibrinolysis syndrome. Additional adverse events included gynecomastia in 37 of 63 patients (59%). Secondary observations included PSA responses in 3 of 9 patients treated with DES after chemotherapy progression and a high rate of PSA responses in patients re-treated with DES after a drug holiday.Low-dose DES is safe and effective in a modern cohort of men with CRPC despite anti-androgen treatment. Its potential role in the post-chemotherapy setting and the suggestion of efficacy on re-challenge merits additional consideration. |
Databáze: | OpenAIRE |
Externí odkaz: |